Melanoma has been at the forefront of precision oncology and immunotherapy for over a decade. The discovery that approximately 50% of cutaneous melanomas harbor BRAF V600E/K mutations led to the development of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib), while the success of ipilimumab and nivolumab established immunotherapy as a curative-intent treatment for advanced disease, with long-term survival exceeding 20% at 10 years in some trials.
Current trials investigate anti-PD-1/LAG-3 combinations (relatlimab/nivolumab, already approved), triple checkpoint blockade, personalized neoantigen vaccines combined with anti-PD-1, tumor-infiltrating lymphocyte (TIL) therapy (lifileucel, FDA approved), and BRAF/MEK inhibitor combinations with immunotherapy for BRAF-mutated disease. Adjuvant trials aim to prevent recurrence in resected high-risk Stage III disease.
BRAF mutation status is required for enrollment in targeted therapy trials. Uveal, mucosal, and acral melanoma subtypes have distinct biology and are studied separately from cutaneous melanoma.
Frequently Asked Questions — metastatic uveal melanoma Clinical Trials
How many clinical trials are currently recruiting for metastatic uveal melanoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for metastatic uveal melanoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic uveal melanoma?
metastatic uveal melanoma research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic uveal melanoma clinical trial?
Eligibility criteria for metastatic uveal melanoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
St Vincent's Hospital, Sydney 1 trial
IDEAYA Biosciences 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: November 2026 ·
Data Methodology